At sites of vascular injury, von Willebrand factor (VWF) mediates platelet adhesion through binding to platelet glycoprotein Ib (GPIb
I-botrocetin binding was normal, suggesting that
Adhesion of platelets to vessel walls is a first step in normal hemostasis and also in thrombotic events such as the occlusion of atherosclerotic arteries. These events are mediated by at least two ligand-receptor interactions: von Willebrand factor (VWF) 1 binding to platelet glycoprotein Ib (GPIb) and fibrinogen binding to platelet GPIIb-IIIa. VWF does not bind spontaneously to platelets in blood, and its adhesive properties are induced in vivo upon the binding of VWF to subendothelial connective tissue, particularly under conditions of high shear stress that occur in the microcirculation (1) . VWF consists of disulfide-linked multimers that are assembled from subunits of Ϸ 250 kDa. The VWF multimers range in size from dimers of Ϸ500 kDa to Ͼ10,000 kDa. VWF binds to an N-terminal domain of the GPIb␣ subunit (2) (3) (4) , and the GPIbbinding site on VWF corresponds approximately to the first of three repeated A domains in the VWF subunit. Domain A1 extends from Glu 497 to Gly 716 and contains an intrachain disulfide loop that is defined by the disulfide bond Cys 509 -Cys 695 (5, 6) . Binding of VWF to GPIb in vitro can be induced by the antibiotic ristocetin or by the snake venom protein botrocetin. Ristocetin apparently can bind both to platelets and to VWF (7) , whereas botrocetin binds to VWF domain A1 but not to GPIb (8) .
By clustered charged-to-alanine scanning mutagenesis, we have found several clustered mutants of charged residues within VWF-A1 domain showing reduced or increased function (9) . Sev 
642
-Lys 645 decreased binding to GPIb, suggesting that several residues within these segments may interact with GPIb. We now have prepared 28 new mutants in which a single charged residue is changed to alanine, and these proteins were used to characterize the binding sites for botrocetin and GPIb. The results suggest that botrocetin and GPIb bind to adjacent sites on the VWF-A1 domain, and the amino acid residues required for ristocetin-induced binding to GPIb are distinct from those required for botrocetin-induced binding.
Transfusion Service), 211A6 (Dr. Claudine Mazurier), and 52K2 (Dr. Zaverio Ruggeri, Scripps Research Institute, La Jolla, CA).
Plasmid Constructs-The strategy for mutagenesis was described previously (9) . A polymerase chain reaction method was used to introduce mutations into plasmid pGEM-4ZNK (11), and each mutation was confirmed by DNA sequencing using a dideoxy termination method (Sequenase 2.0, U. S. Biochemical Corp.). The mutated NgoMI-KpnI fragments then were cloned into pSVHVWF1.1 (9) .
Expression and Characterization of Recombinant VWF-Human 293T cells (12) were grown in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Life Technologies, Inc.). Cells were transfected by a calcium-phosphate method and recombinant VWF (rVWF) secreted in the medium was harvested and concentrated by ultrafiltration as described (9) . VWF antigen was measured by an ELISA using polyclonal rabbit anti-human VWF antibody 082 and peroxidase-conjugated rabbit anti-human VWF antibody 226 (DAKO) (13) . Multimer analysis was performed as described (14) .
Binding of VWF to mAb Panel-The IgG fractions of mAbs NMC-4, AVWF3, 52K2, CLB-RAG34, and CLB-RAG35 were isolated from ascites fluid by chromatography on recombinant protein A-agarose (Amersham Pharmacia Biotech). Binding was assessed by ELISA using microtiter plates with U-shaped bottoms (Coster, Cambridge, MA). Plates were coated with 25 l of each mAb (7.5 g/ml) in 0.1 M sodium carbonate, pH 9.6, for 24 h at 4°C. The wells were washed with phosphate-buffered saline (PBS) containing 0.1% Tween 20 and then incubated with various concentrations of wild type or mutant rVWF diluted in PBS containing 3% bovine serum albumin (Sigma). The wells were washed again and incubated with antibody 226 diluted in PBS containing 3% bovine serum albumin color development with o-phenylenediamine, and the absorbance at 490 nm was determined. Binding of rVWF mutants was determined at a fixed concentration of rVWF (500 ng/ml) and normalized to the value obtained for wild type rVWF in paired assays. Negative control assays were performed by using concentrated conditioned medium from mock-transfected 293T cells.
125
I-Botrocetin Binding Assays-Botrocetin binding to VWF was assayed according to methods of Fujimura et al. (15) as described previously (9) . The assay was performed using anti-VWF mAb 33E12 that binds to the C-terminal region of the VWF subunit. It has no effect on VWF binding to platelets in the presence of either ristocetin or botrocetin (16) . In brief, botrocetin was radioiodinated with 125 I using a chloramine-T method (17) . Microtiter plates were coated with 25 l of 33E12 (7.5 g/ml) for 16 h at 4°C. The wells were washed, blocked, and incubated with 15 l of each rVWF mutant (5 g/ml) for 3 h at room temperature. The wells were washed again, and 5 l of 125 I-labeled botrocetin solution was added for 30 min at room temperature. Following rapid washing, air dried wells were excised and the bound radioactivity was measured by ␥ spectroscopy. Nonspecific binding was obtained by assaying culture supernatant from mock-transfected cells, and specific binding was calculated by subtracting nonspecific from total binding. Values for mutant proteins at 3 g/ml of 125 I-botrocetin were normalized to paired values for wild type rVWF. mAb B724 was assayed for ability to inhibit I-botrocetin (3 g/ml), and the indicated amount of mAb B724 or control mouse IgG (DAKO) was added and then incubated for 30 min at room temperature. After washing, the bound radioactivity was measured as described above. The observed botrocetin binding was normalized to the value obtained in the absence of competing IgG.
Platelet Binding Assays-Assays were performed as described previously (9) . To assay botrocetin-induced binding of VWF to GPIb, 570 ng/ml of rVWF was mixed with 2 ϫ 10 8 /ml of lyophilized human platelets (Biodata, Hatboro, PA) and incubated with various concentrations (0 -10 g/ml) of botrocetin. After 30 min at room temperature, the VWF antigen present in the centrifuged supernatant was measured by ELISA. Data for botrocetin concentrations bracketing the midpoint of the dose response curve (2, 3, and 6 g/ml) were pooled for statistical analysis. To assay ristocetin-induced binding of VWF to GPIb, 500 ng/ml of rVWF was mixed with 2 ϫ 10 8 /ml of platelets, 4% bovine serum albumin, and various concentrations (0 -1.5 mg/ml) of ristocetin (Helena Laboratories, Beaumont, TX). After 30 min at room temperature, the VWF in the centrifuged supernatant was measured by ELISA. Reaction mixtures without platelets were tested simultaneously to verify the absence of nonspecific VWF flocculation and sedimentation in the presence of ristocetin. The unbound VWF was expressed as a percentage of the values obtained with no modulators, and the percentage of bound VWF was calculated by subtraction from 100%. The percentage of bound VWF was normalized to the paired value obtained for wild type rVWF assayed concurrently. Data at 1.5 mg/ml ristocetin were used for statistical analysis.
Statistical Analysis-Means and S.D. were calculated by standard methods. Confidence intervals (p Ͻ 0.05) for the means were estimated using the t distribution where the interval is given by the means Ϯ S.D.
Crystallographic Structure Representations-Connelly surface plots of the VWF A1 domain were prepared with the program INSIGHT II (Molecular Simulations, San Diego, CA). Schematic drawings of secondary structure elements of domain A1 were prepared with the program MOLSCRIPT (18) .
RESULTS

Design and Expression of VWF A1 Domain
Mutants-In a previous study by charged-to-alanine scanning mutagenesis, we identified 6 single mutants and 13 clustered mutants with defects in binding to either botrocetin or platelet GPIb. From these data, the binding site for botrocetin or GPIb required amino acid residues within four segments of the VWF-A1 domain: 514 -534, 549 -552, 596 -645, and 663-667 ( Fig. 1) (9) . Other reports suggested that binding to GPIb and heparin required residues within the segment 569 -573 (19) , and preliminary studies indicated that monoclonal antibody B724 (20) did not bind to construct (656 -660)2A.
We further studied these six segments by constructing 28 additional single charged-to-alanine mutations (Fig. 1) . Human kidney 293T cells were transfected with each mutant construct, and serum-free media were analyzed for the expression of rVWF. All 28 mutants were expressed and secreted efficiently. The multimer distribution of all mutant proteins was similar to that of wild type rVWF and plasma VWF; in every case, at least 12 multimer bands were detected (data not shown).
rVWF Binding to Monoclonal Antibodies-The folding of the A1 domain with each rVWF protein was evaluated with a panel of six conformation-dependent monoclonal antibodies: NMC-4 FIG. 1. Amino acid residues of human VWF targeted for charged-to-alanine mutagenesis. The amino acid sequence shown includes a part of domain D3 (463-496) and the entire A1 domain (497-716). The secondary structure elements of the A1 domain as determined by Celikel et al. (27) are indicated below the sequence (␣, ␣-helix; ␤, ␤-strand). Charged residues His, Arg, Lys, Glu, and Asp were targeted for the mutagenesis and are shown by characters in red. Previously studied clustered mutants have alanine mutations at more than one charged amino acid residue in a single construct (9) and are indicated by single underlines. The extent of the underlining indicates the residues mutated in a single construct. For example, construct (527-531)3A contained alanine substitutions at the three charged residues Glu 527 , Glu 529 , and Glu
531
. For the 11 clustered mutations shown, 28 corresponding single charged-to-alanine mutations were produced and are indicated by yellow boxes. Six additional single mutants that were constructed previously (9) are indicated by yellow boxes with double underlines. (21, 22) , AvWF3 (23), CLB-RAG34, CLB-RAG35 (24), B724 (20) , and 211A6 (25) . Recognition of domain A1 by these antibodies is impaired by reduction or denaturation. Antibody 52K2 reacts with both reduced and nonreduced forms of VWF (21) and was used as a control. For each antibody, the absorbance value obtained for each mutant rVWF was expressed as a percentage of the value obtained for wild type rVWF (Fig. 2) . All rVWF proteins displayed normal binding to mAb 52K2. Concentrated conditioned medium from mock transfected cells gave no signal with any of these antibodies.
Mutants D514A, D520A, R552A, and R611A showed markedly decreased binding to all six conformation-dependent mAbs (Fig. 2) , suggesting that these substitutions cause significant misfolding of the A1 domain. Therefore, although further ligand binding data were obtained for these proteins, the results were excluded from additional interpretation. In fact, the binding of this class of mutants to botrocetin and GPIb was reduced Ͼ70% in all assays (data not shown). Mutant K534A showed decreased binding to four mAbs (AvWF3, CLB-RAG34, CLB-RAG35, and B724), although it retained nearly normal binding to two others (NMC-4 and 211A6). Thus, Lys 534 is at least required for the presentation of epitopes for several antibodies and may be important to maintain the normal conformation of the A1 domain.
Other substitutions caused relatively selective defects in mAb binding. For example, at a concentration of 0.5 g/ml mutant rVWF, binding to mAb B724 was decreased markedly by the mutations K660A and R663A (Fig. 2) . These mutants showed normal binding to all other antibodies. Dose response binding curves illustrate the substantial decrease in affinity caused by the substitution K660A or R663A (Fig. 3) botrocetin, but their significance was uncertain because these mutations also impaired binding to mAb NMC4 so that protein misfolding could not be excluded (9) .
To address this uncertainty, additional rVWF mutants were constructed and assayed for binding to 3 g/ml 125 I-botrocetin (Fig. 4) . At this concentration of botrocetin, binding to VWF is approximately half of the maximum (9, 15) . Four previously constructed proteins that had shown decreased binding to GPIb or botrocetin were included as well: K534A, E626A, R632A, and R636A.
Four mutants exhibited decreased binding Ͻ60% of wild type rVWF: R629A, R632A, R636A, and K667A. As discussed below, the mutations R629A and R632A also disrupt binding to GPIb induced by ristocetin, whereas the mutations R636A and K667A do not. Therefore, the side chains of Arg 636 and Lys 667 are specifically required for binding to botrocetin. As reported previously for plasma VWF (20) , mAb B724 inhibited the binding of botrocetin to immobilized wild type rVWF (data not shown).
Although botrocetin binding was markedly reduced by the clustered mutation of four lysine residues in construct (642-645)4A (9), the individual mutation of each lysine had a modest effect on binding to botrocetin (Fig. 4) , suggesting that no one of these residues makes a substantial contribution to this interaction. Similarly, the clustered mutant (613-616)2A exhibited markedly impaired binding to botrocetin (9) , but the corresponding single mutants E613A and R616A bound with slightly decreased affinity to botrocetin (Fig. 4) .
Binding of rVWF to GPIb-Binding to GPIb was assessed by quantitating the rVWF that bound to formalin-fixed platelets in the presence of ristocetin (1.5 mg/ml) or botrocetin (2-6 g/ml). In either case, binding to platelets was blocked completely by a mAb 6D1 to platelet GPIb (10) as reported previously (26) . Values for each mutant protein were normalized to those obtained for control assays of wild type rVWF.
The VWF mutants R524A, E529A, E531A, K549A, K569A, D570A, R573A, K608A, D610A, K643A, K644A, K645A, H656A, K660A, R663A, and E666A displayed binding to GPIb that was Ͼ60% of wild type rVWF in the presence of ristocetin or botrocetin (Fig. 5) . These mutants also showed essentially normal 125 I-botrocetin binding (Fig. 4) , suggesting that the corresponding amino acid side chains are not directly involved in the interactions of VWF with GPIb, ristocetin, or botrocetin.
The mutants R636A and K667A showed decreased botrocetin-induced GPIb binding (Fig. 5 ) that is consistent with their decreased binding to 125 I-botrocetin (Fig. 4) . However, these proteins retained normal ristocetin-induced GPIb binding (Fig.  5) ) decreased ristocetininduced GPIb binding without affecting botrocetin-induced GPIb binding (Fig. 5) or 125 I-botrocetin binding (Fig. 4) . Therefore, these sites appear to be required for ristocetin-dependent VWF modulation but not for direct interaction with GPIb.
Mutation at a residue that directly interacts with GPIb would be predicted to reduce both ristocetin-induced and botrocetin-induced GPIb binding, and three mutants had this phenotype: K599A, R629A, and R632A. Among them, only K599A retained normal binding to 125 I-botrocetin. Because GPIb and botrocetin can bind simultaneously to VWF, the selective loss of GPIb binding suggests that Lys 599 interacts directly with GPIb and not with botrocetin. The mutants R629A and R632A decreased binding to both GPIb and 125 I-botrocetin, suggesting that these amino acid side chains could be involved in the binding of both ligands. each side (Fig. 6) . A disulfide bond at one end of the ␤-sheet links the N-terminal and C-terminal ends, and the sequence flanking the disulfide bond at the N terminus of the domain lies across its lower surface. These structures provide a framework for interpreting the effects of charged-to-alanine mutations on ligand binding.
Binding Sites for GPIb, Botrocetin, and Monoclonal Antibodies-K599A was the only VWF A1 mutant that retained normal binding to botrocetin and lost both ristocetin-induced and botrocetin-induced binding to GPIb. This specific effect suggests that the GPIb-binding site involves Lys 599 , which is located in the middle of helix 3 (Fig. 6) . The mutations R629A and R632A in the adjacent helix 4 impaired binding to GPIb but also decreased botrocetin binding, suggesting that Arg 629 or Arg 632 may interact with both GPIb and botrocetin. However, the interpretation of this dual defect is complicated by the strong positive cooperativity between botrocetin and GPIb binding. Because of this linkage, a single mutation in domain A1 might reduce the affinity for both ligands by interfering with allosteric changes rather than by disrupting a common binding site. The mutations R636A and K667A have a simpler phenotype, impairing botrocetin binding (Fig. 4) but not ristocetin-induced binding to GPIb (Fig. 5) . The selective effect of these mutations indicates that the botrocetin-binding site is, in fact, adjacent to the GPIb-binding site and spans both helix 4 and helix 5 (Fig. 6) .
This position for the botrocetin site is supported by the localization of epitopes for two monoclonal antibodies that compete for botrocetin binding, NMC-4 (29) and B724 (20) . The crystallographic structure of the complex (27) shows that the NMC-4 Fab fragment interacts directly with the amino acid side chains of Arg 629 , Arg 632 , and Arg 636 of helix 4 in the VWF A1 domain (Fig. 6) . The mutation R632A decreased the binding of NMC-4 (9) (Fig. 2 ) and is compatible with the location of the NMC-4 epitope. The binding sites for NMC-4 and botrocetin therefore both appear to contain Arg 636 , and this overlap explains their competitive interaction with VWF (Fig. 6) . The proximity of the NMC-4 epitope to the proposed GPIb site involving Lys 599 also is consistent with the ability of NMC-4 to inhibit the binding of VWF to platelets (22, 29) .
In contrast to NMC-4, antibody B724 does not prevent the binding of VWF to platelets in the presence of ristocetin (20) , suggesting that its epitope is distant from the GPIb site but close to the botrocetin site. This conclusion is supported by the results of mutagenesis (Fig. 2) , which indicate that the B724 epitope contains residues Lys 660 and Arg 663 on helix 5 (Fig. 6 ). The adjacent residue Lys 667 contributes to the botrocetin-binding site and probably accounts for the ability of B724 to inhibit botrocetin binding to VWF (20) .
These results suggest a model for the location of several binding sites on the VWF A1 domain (Fig. 6) . Platelet GPIb␣ interacts with a site that includes Lys 599 within helix 3. Botrocetin binding requires residues in both helices 4 and 5 that are within or adjacent to the epitopes for NMC-4 and B724, respectively. NMC-4 binds to helix 4 at a site that is sufficiently close to the GPIb site to prevent the binding of VWF to platelets. Antibody B724 binds to helix 5 at a site too remote to interfere with GPIb binding. All of these binding sites involve helices that are on the same side of the central ␤-sheet within the VWF A1 domain.
Selective Loss of Ristocetin-induced Binding to GPIb-Mutations that abolish the modulation of VWF activity by ristocetin frequently preserve modulation by botrocetin, and this phenotype indicates that ristocetin and botrocetin promote VWF binding to GPIb by fundamentally different mechanisms. Eight VWF mutations (K534A, R571A, K572A, E596A, E613A, R616A, E626A, and K642A) caused a selective decrease in ristocetin-induced binding to platelets. A few patients with severe bleeding and von Willebrand disease type 2M have plasma VWF with a similar phenotype. In three such cases, mutations within the A1 domain have been characterized by expression studies: G561S, F606I, and I662F (26, 30) . In other patients with VWD type 2M, candidate mutations were identified that involve residues also implicated by alanine mutagenesis, including deletion of Lys 642 and E596K (31) . The mechanism by which ristocetin induces VWF to bind platelets is not understood. All but three of the mutations that selectively impair ristocetin-induced binding to GPIb␣ are on the same side of the central ␤-sheet as the binding sites for GPIb␣ and botrocetin. Because botrocetin remains capable of inducing high affinity binding to platelets, the affected amino acid residues are not required for binding to GPIb␣. Instead they may be required for ristocetin binding or contribute to binding under conditions of fluid shear stress, or mutations at these positions may prevent conformational changes induced by ristocetin. The five residues known to be mutated in patients with VWD type 2M (Gly (Fig. 7) , and mutations at these positions could prevent the normal exposure of the GPIb-binding site during platelet adhesion.
Regulation of VWF Binding to GPIb-A remarkable subtype of VWD, referred to as type 2B, is characterized by mutant VWF that has increased affinity for platelet GPIb␣. In vivo, the larger VWF multimers bind spontaneously to platelets and are cleared from the circulation. The remaining small VWF multimers do not function normally, and the patients bleed. Mutations that cause VWD type 2B are known to affect 15 amino acid residues in the VWF A1 domain (32) (33) (34) (35) , and they cluster on one side of the central ␤-sheet (Fig. 8) . Interestingly, all of these residues are located on the side opposite the GPIb-binding site, which includes Lys 599 . The cluster of VWD type 2B mutations appears to mark the location of a regulatory site that normally inhibits the binding of domain A1 to GPIb␣. Mutations affecting the regulatory site can relieve this inhibition and cause the constitutive binding that characterizes VWD type 2B (9, 36, 37) . A challenge for the future is to determine how mutations on one side of domain A1 can activate a GBIbbinding site on the opposite side and whether this apparently allosteric regulation of VWF-platelet interactions is important for normal hemostatis.
